CLINICAL TRIALS PROFILE FOR ANDROID 5

All Clinical Trials for ANDROID 5

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03387787 ↗	Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2	Completed	University Hospital Inselspital, Berne	Phase 2/Phase 3	2018-01-30	The GlucoTab® system is a computerized decision support system built of an android based front-end user interface and a backend server including the REACTION algorithm. GlucoTab® is able to process blood glucose data and physiological confounders of glycaemia. Subsequently, GlucoTab® provides patient-specific basal, bolus, and correction insulin doses together with visualization and documentation of relevant data. The GlucoTab® system was found capable to keep hospitalized diabetic patients in the recommended target range without increasing the risk for hypoglycaemic events. Insulin pharmacokinetic is a critical confounder of glycaemic variability and the main determinant of an algorithm-based decision support-system. GlucoTab® is intended for being used with a basal/bolus insulin regimen. Up to date, feasibility data are limited to the use of insulin glargine. Insulin degludec, an ultra-long acting basal insulin is characterized by a stable pharmacokinetic profile a half-life of ~25 hours. It was found equally effective to insulin glargine with respect to glycaemic control, while the incidence of (nocturnal) hypoglycaemia was smaller in patients treated with insulin degludec. Within the present study, insulin glargine will be replaced by insulin degludec, which is not yet approved for dose titration with GlucoTab®. In the present study, 15 non-critically ill T2DM patients, who were hospitalized at the University Clinic of Neurosurgery for various reasons and require insulin treatment will be recruited. Patients will be treated with insulin Tresiba and insulin Novorapid. For a maximum duration of 21 days, GlucoTab® will calculate the required insulin doses for each patient, depending on fasting plasma glucose and postprandial glucose measurements during the day. After the calculated Insulin dose has been approved by the physician, the nursing staff will give the dose to the respective patient. The present study will analyse the efficacy of GlucoTab® for glycaemic management in T2DM patients using insulin degludec.
NCT02897934 ↗	CWI and Discharge After Breast Cancer Surgery	Completed	University College Cork		2016-08-01	The objectives of this work are threefold: 1. To evaluate the analgesic efficacy of CWI in women discharged within 23 hours of major breast cancer surgery 2. To evaluate objective indices of patient recovery following anaesthesia and surgery in a 23 hour model of care 3. To evaluate patient satisfaction with their care pathway
NCT02107014 ↗	Low Dose Naltrexone (LDN) Immune Monitoring	Completed	Stanford University	N/A	2014-03-01	We have found that low dose naltrexone (LDN) can substantially reduce pain associated with fibromyalgia syndrome. We believe LDN may work via novel anti-inflammatory channels. The purpose of this study is to determine if LDN lowers inflammatory markers in individuals with fibromyalgia.
NCT02107014 ↗	Low Dose Naltrexone (LDN) Immune Monitoring	Completed	University of Alabama at Birmingham	N/A	2014-03-01	We have found that low dose naltrexone (LDN) can substantially reduce pain associated with fibromyalgia syndrome. We believe LDN may work via novel anti-inflammatory channels. The purpose of this study is to determine if LDN lowers inflammatory markers in individuals with fibromyalgia.

Clinical Trial Conditions for ANDROID 5

Condition Name

Condition Name for ANDROID 5
Intervention	Trials
Breast Cancer	2
Quitting Smoking	1
Kidney Transplant Failure	1
Renal Failure	1

Condition MeSH

Condition MeSH for ANDROID 5
Intervention	Trials
Diabetes Mellitus	3
Diabetes Mellitus, Type 1	1
Postoperative Nausea and Vomiting	1
Diabetes Mellitus, Type 2	1

Clinical Trial Locations for ANDROID 5

Trials by Country

+

−

Trials by Country for ANDROID 5
Location	Trials
Canada	4
United States	3
Switzerland	2
Ireland	1

Trials by US State

+

−

Trials by US State for ANDROID 5
Location	Trials
Vermont	1
Pennsylvania	1
California	1

Clinical Trial Progress for ANDROID 5

Clinical Trial Phase

Clinical Trial Phase for ANDROID 5
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for ANDROID 5
Clinical Trial Phase	Trials
Recruiting	3
Completed	3
Not yet recruiting	2

Clinical Trial Sponsors for ANDROID 5

Sponsor Name

Sponsor Name for ANDROID 5
Sponsor	Trials
Stanford University	2
Penn State University	1
University Hospital of North Norway	1

Sponsor Type

Sponsor Type for ANDROID 5
Sponsor	Trials
Other	18

Clinical Trials, Market Analysis, and Projections: A Comprehensive Overview

Introduction to Clinical Trials

Clinical trials are pivotal in the development and approval of new drugs and medical treatments. These trials are designed to evaluate the safety, efficacy, and effectiveness of new interventions in humans. Here, we will delve into the current state of clinical trials, market analysis, and projections, although the specific drug "Android 5" is not mentioned in the available sources, we will provide a general overview that can be applied to any new drug in development.

The Clinical Trial Process

Phases of Clinical Trials

Clinical trials typically progress through four phases:

• Phase I: This phase assesses the safety and dosage of the treatment in a small group of healthy volunteers or patients. It determines how the drug is absorbed, metabolized, and excreted, and investigates potential adverse reactions[3].
• Phase II: This phase expands the study to a larger group to further evaluate the safety and efficacy of the drug.
• Phase III: This phase involves even larger populations to confirm the drug's effectiveness, monitor side effects, and compare it to standard treatments.
• Phase IV: Conducted after FDA approval, this phase gathers additional information on the treatment's risks, benefits, and optimal use[3].

Market Analysis of Clinical Trials

Global Clinical Trials Market

The global clinical trials market was valued at USD 84.61 billion in 2024 and is projected to reach USD 146.60 billion by 2033, growing at a CAGR of 6.07% during the forecast period (2025–2033). This growth is driven by the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders, which has led to a surge in demand for new drug development[3].

Key Drivers and Restraints

• Drivers: The increasing demand for new treatments due to rising chronic diseases, government initiatives and funding, and the integration of real-time data analytics in the healthcare industry are significant drivers[3].
• Restraints: Regulatory and privacy issues, lack of transparency, and delayed access to treatment are some of the challenges faced by the clinical trials market[2].

Drug Utilization Management Market

Overview

The U.S. drug utilization management market is another critical aspect to consider when discussing clinical trials and new drug development. This market is anticipated to reach USD 60.68 billion by 2030, exhibiting a CAGR of 7.30% from 2024 to 2030. The growth is primarily influenced by the increasing introduction of innovative yet high-priced drugs, leading to efforts by payers to manage spending and by pharmaceutical manufacturers to support patient access and sales[2].

Strategies and Trends

• Payer Strategies: Payers are implementing strategies like restricting drug formularies, stringent prior authorizations, and raising patient cost-sharing requirements to manage spending.
• Manufacturer Strategies: Manufacturers are investing in programs to assist patients and physicians in navigating administrative controls and meeting cost-sharing obligations[2].

Specific Conditions and Trials

Example: Alzheimer's Disease

The National Institute on Aging (NIA) is currently supporting over 500 active clinical trials on Alzheimer’s disease and related dementias. These trials reflect diverse drug and mechanistic targets, including anti-Aβ immunotherapy and small molecule sigma2 receptor antagonists. For instance, the trial "A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease" is ongoing, highlighting the extensive research efforts in this area[4].

Market Projections for New Drugs

General Trends

For a new drug like "Android 5," market projections would depend on several factors, including the phase of clinical trials it is in, the target condition, and the competitive landscape.

• Phase I Success: If the drug successfully navigates Phase I, it sets a positive trajectory for further development. Phase I studies evaluate the safety and tolerability of the drug, which is crucial for securing funding and investor confidence[3].
• Market Demand: The demand for the drug will be influenced by the prevalence of the target condition and the existing treatment options. For example, drugs targeting chronic diseases like diabetes or cancer are likely to have high market demand[3].

Key Takeaways

• Clinical Trial Phases: Understanding the different phases of clinical trials is essential for evaluating the progress and potential of a new drug.
• Market Growth: The global clinical trials market and drug utilization management market are growing due to increasing demand for new treatments and efforts to manage healthcare costs.
• Regulatory and Competitive Landscape: Navigating regulatory hurdles and competitive strategies is crucial for the successful launch and market penetration of a new drug.
• Target Conditions: The success of a drug is heavily influenced by the prevalence and treatment landscape of the target condition.

FAQs

What are the main phases of clinical trials?

Clinical trials typically progress through four phases: Phase I (safety and dosage), Phase II (safety and efficacy in a larger group), Phase III (effectiveness and side effects in a large population), and Phase IV (post-approval monitoring)[3].

How is the global clinical trials market projected to grow?

The global clinical trials market is projected to grow from USD 91.50 billion in 2025 to USD 146.60 billion by 2033, at a CAGR of 6.07% during the forecast period[3].

What drives the growth of the U.S. drug utilization management market?

The growth is primarily driven by the increasing introduction of innovative yet high-priced drugs, leading to efforts by payers to manage spending and by pharmaceutical manufacturers to support patient access and sales[2].

What are some common strategies used by payers in drug utilization management?

Payers use strategies like restricting drug formularies, stringent prior authorizations, and raising patient cost-sharing requirements to manage spending[2].

How do government initiatives impact clinical trials?

Government initiatives and funding support clinical trials, creating opportunities for global market expansion and driving the demand for new treatments[3].

Sources

1. Lilly Clinical Trials: Find Lilly Clinical Trials - Search Lilly clinical trials to find an appropriate trial near you or a loved one, or sign up to receive alerts on Lilly trials.
2. U.S. Drug Utilization Management Market: U.S. Drug Utilization Management Market Size, Share & Trends Analysis Report 2024-2030 - ResearchAndMarkets.com.
3. Global Clinical Trials Market: Global Clinical Trials Market Size, Top Share, Trends, Forecast by Straits Research.
4. NIA-Funded Active Alzheimer’s and Related Dementias Clinical Trials: NIA-Funded Active Alzheimer’s and Related Dementias Clinical Trials and Studies - National Institute on Aging.